IO Biotech Appoints Heidi Hunter to its Board of Directors
11 August 2023 - 2:05PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® technology platform, announced the appointment of
Heidi Hunter to its board of directors. Ms. Hunter, an accomplished
global biotech leader with over 25 years of experience across the
pharmaceutical value chain, from clinical and commercial
development through to launch execution, will serve on the Audit
Committee and the Nominating and Corporate Governance Committee of
the Board. In addition, Priyanka Belawat, PhD, has announced that
she is stepping down from the company’s board of directors,
effective immediately.
“We are delighted to welcome Heidi to the IO
Biotech Board,” said Mai-Britt Zocca, PhD, President and CEO of IO
Biotech. “Her extensive experience in innovation, development and
commercialization of specialty pharmaceuticals will be instrumental
as we continue to advance IO102-IO103 through our ongoing Phase 3
pivotal trial in first-line advanced melanoma. With the interim
read out from this trial expected in mid-2024 that could
potentially support a BLA submission with the FDA, Heidi’s
expertise will be particularly helpful as we begin our commercial
planning. We look forward to her many contributions as we work to
change the current treatment paradigm with innovative vaccine
options for people with cancer.”
Ms. Hunter commented, “It is a privilege to be
joining the IO Biotech Board at this exciting time for the company.
Upcoming data readouts could provide significant opportunities to
accelerate the path forward for IO102-IO103. I look forward to
bringing my experience in developing and commercializing new
medicines to support IO Biotech with advancing this novel vaccine
that has the potential to change the treatment landscape for cancer
patients.”
“Additionally, on behalf of our board of
directors and management team, we thank Priyanka for her many years
of service and valuable contributions she has made to IO Biotech,”
added Dr. Zocca.
Ms. Hunter most recently served as President of
Cardinal Health where she led the Specialty Solutions Business.
Prior to Cardinal Health, Ms. Hunter was Senior Vice President of
the Global Immunology Business Unit at UCB in Brussels from
September 2015 to September 2020. She has also held leadership
positions at Boehringer Ingelheim as Senior Vice President and
General Manager in its Biosimilars Business, and at IQVIA as Vice
President of Global Business Partnerships Commercial Solutions.
Ms. Hunter also held senior leadership positions
in commercial and strategic marketing for biologics and oncology at
Centocor, a Johnson & Johnson company. She also led the
oncology business at Wyeth (today part of Pfizer) in the United
States and CNS and women’s health at Novo Nordisk in Denmark. Early
in Ms. Hunter’s career, she held sales and marketing positions at
Ciba-Geigy in Switzerland (today part of Novartis). She is
currently on the boards of Bavarian Nordic A/S, Vicore Pharma
Holdings AB and Sutro Biopharma, Inc. Ms. Hunter earned a B.A. from
The University of Michigan and her M.B.A. from The University of
Chicago – Booth School of Business.
About IO102-IO103
IO102-IO103 is an investigational
immune-modulating cancer vaccine designed to target the
immunosuppressive mechanisms mediated by the proteins indoleamine
2,3-dioxygenase (IDO) and PD-L1. The company is currently
conducting a Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating
IO102-IO103 in combination with pembrolizumab in first-line
advanced melanoma patients, and a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709).
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® vaccine platform. The T-win platform is a novel
approach to cancer vaccines designed to activate T cells to target
the most important immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing in clinical studies its
lead cancer vaccine candidate, IO102-IO103, targeting IDO and
PD-L1, and through preclinical development its other pipeline
candidates. IO Biotech is headquartered in Copenhagen, Denmark and
has US headquarters in New York, New York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding future clinical trials and results, are based on IO
Biotech’s current assumptions and expectations of future events and
trends, which affect or may affect its business, strategy,
operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024